Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D/A 0001829126-26-004104 0002022463 XXXXXXXX LIVE 2 Common Stock, par value $0.01 per share 06/24/2026 false 0001857044 45339J105 Indaptus Therapeutics, Inc. c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY 10019 Junyi Dai (646) 427-2727 c/o Indaptus Therapeutics, Inc., 3 Columbus Circle, 15th Floor, New York NY 10019 0002022463 N Dai Junyi PF N C3 11250000.00 0.00 11250000.00 0.00 11250000.00 N 8.44 IN Junyi Dai beneficially owns 11,250,000 shares of the Issuer's Common Stock. Such shares were acquired pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement"), and were issued upon the conversion of the Issuer's Series AA and Series AAA Preferred Stock in connection with the closing of the transaction on March 23, 2026. All percentage calculations herein are based on 133,242,324 shares of Common Stock outstanding of the issuer as of June 24, 2026, based on information provided in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 24, 2026. Please also refer to the Schedule 13D filed by Yun Yao on behalf of Yun Yao, Sino Lion Ventures Limited, Chenhao Xu, Junyi Dai, Ting Yang and Lina Deng with the Securities and Exchange Commission on March 30, 2026 and all amendments to date. Common Stock, par value $0.01 per share Indaptus Therapeutics, Inc. c/o Indaptus Therapeutics, Inc. 3 Columbus Circle, 15th Floor New York NY 10019 Explanatory Note. This Amendment No. 2 ("Amendment No. 2") to Schedule 13D relates to the common stock, par value $0.01 per share (the "Common Stock") of Indaptus Therapeutics Inc., a Delaware corporation (the "Issuer"), and amends and supplements the initial statement on Schedule 13D originally filed by Yun Yao on behalf of Yun Yao, Sino Lion Ventures Limited, Chenhao Xu, Junyi Dai ("Reporting Person"), Ting Yang, and Lina Deng with the Securities and Exchange Commission ("SEC") on March 30, 2026, as amended by Amendment No. 1 filed on April 29, 2026 to report the disbandment of such group (collectively, the "Initial Schedule 13D", and as amended and supplemented by this Amendment No. 2, the "Schedule 13D"). Capitalized terms used but not defined in this Amendment No. 2 shall have the same meanings ascribed to them in the Initial Schedule 13D. Mr. Junyi Dai, an individual. Mr. Dai's address is c/o Indaptus Therapeutics, Inc., 3 Columbus Circle, 15th Floor, New York, NY, 10019. Mr. Dai's present principal occupation is the chief executive officer and chairman of Indaptus Therapeutics, Inc. During the last five years, Mr. Dai has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). During the last five years, Mr. Dai has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, which as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, United States federal or state securities laws or finding any violation with respect to such laws. Mr. Dai is a citizen of the Australia. The Series AAA Preferred Stock was purchased by Mr. Dai pursuant to the Securities Purchase Agreement, dated as of March 19, 2026 (the "Purchase Agreement") between David Lazar, Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng. The Purchase Agreement closed on March 23, 2026. Mr. Dai used personal funds in the aggregate amount of $1,156,642.43 to fund his purchase. The information set forth in Item 4 in the Initial Schedule 13D is incorporated herein by reference. This Amendment No. 2 is being filed to report a decrease of more than 1% in the percentage of the outstanding Common Stock beneficially owned by the Reporting Person, resulting solely from the increase in the number of shares of Common Stock issued and outstanding upon the closing of the Issuer's private placement on June 17, 2026. The Reporting Person did not acquire or dispose of any shares of Common Stock in connection therewith. The information contained on the cover pages to this Schedule 13D is incorporated herein by reference. As of the date hereof, there are 133,242,324 shares of Common Stock outstanding as of June 24, 2026, as calculated based on the Issuer's Form 8-K filed with the SEC on June 24, 2026. The following table sets forth the number of Common Stock as to which the Reporting Person has (i) the sole power to vote or direct the vote, (ii) shared power to vote or to direct the vote, (iii) sole power to dispose or to direct the disposition, or (iv) shared power to dispose or to direct disposition: The Reporting Person have not effected any transaction in the shares of Common Stock during the past 60 days. No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the common stock beneficially owned by the Reporting Person. Not applicable. The information set forth in Item 6 in the Initial Schedule 13D is incorporated herein by reference. The information set forth in Item 3 and Item 4 above is incorporated herein by reference. Not applicable. Dai Junyi /s/ Junyi Dai Junyi Dai 06/26/2026